Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Insider Filings - INGRAM ROBERT ALEXANDER
Last Updated 
7-Dec-16
Enter symbol:
symbol lookup

 

EDGAR Online: Get a Free Trial to EDGAR Online Premium | Full text Search

INGRAM ROBERT ALEXANDER: Declared Holdings
Company/RelationshipReportedShares  Ownership
BioCryst Pharmaceuticals, Inc.
Director
NasdaqGS:BCRX
(historical quotes, profile, SEC, other insiders)
1-Sep-162,433  Direct
Cree, Inc.
Director
NasdaqGS:CREE
(historical quotes, profile, SEC, other insiders)
19-Oct-1659,817  Direct
Edwards Lifesciences Corporatio
Director
NYSE:EW
(historical quotes, profile, SEC, other insiders)
15-May-1532,367  Direct
Novan, Inc.
Director
NasdaqGM:NOVN
(historical quotes, profile, other insiders)
26-Sep-1657,777  Direct
Regeneron Pharmaceuticals, Inc.
Director
NasdaqGS:REGN
(historical quotes, profile, SEC, other insiders)
27-May-151,500  Direct
Valeant Pharmaceuticals Interna
Director
NYSE:VRX
(historical quotes, profile, other insiders)
30-Sep-1688,463  Direct

Insider & restricted shareholder transactions reported over the last two years
DateSharesStockTransaction
19-Oct-16 1,115CREE Acquisition (Non Open Market) at $22.41 - $22.41 per share.
(Value of about $25,000)
30-Sep-16 865VRX Acquisition (Non Open Market) at $24.55 - $24.55 per share.
(Value of about $21,000)
26-Sep-16 27,777NOVN Acquisition (Non Open Market) at $0 per share.
20-Sep-16 30,000NOVN Statement of Ownership
1-Sep-16 2,433BCRX Acquisition (Non Open Market) at $4.11 - $4.11 per share.
(Value of about $9,999)
1-Sep-16 6,429CREE Acquisition (Non Open Market) at $0 per share.
17-Aug-16 1,229CREE Acquisition (Non Open Market) at $23.38 - $23.38 per share.
(Value of about $29,000)
30-Jun-16 1,080VRX Acquisition (Non Open Market) at $20.14 - $20.14 per share.
(Value of about $22,000)
17-Jun-16 16,726VRX Acquisition (Non Open Market) at $0 per share.
2-May-16 926VRX Acquisition (Non Open Market) at $0 per share.
27-Apr-16 1,105CREE Acquisition (Non Open Market) at $26 - $26 per share.
(Value of about $29,000)
20-Jan-16 1,093CREE Acquisition (Non Open Market) at $26.30 - $26.3 per share.
(Value of about $29,000)
31-Dec-15 239VRX Acquisition (Non Open Market) at $0 per share.
1-Dec-15 3,750CREE Sale at $27.67 - $27.67 per share.
(Proceeds of about $104,000)
1-Dec-15 3,750CREE Option Exercise at $14.71 - $14.71 per share.
(Cost of about $55,000)
21-Oct-15 1,199CREE Acquisition (Non Open Market) at $23.96 - $23.96 per share.
(Value of about $29,000)
30-Sep-15 136VRX Acquisition (Non Open Market) at $0 per share.
1-Sep-15 6,674CREE Acquisition (Non Open Market) at $0 per share.
12-Aug-15 1,112CREE Acquisition (Non Open Market) at $26.58 - $26.58 per share.
(Value of about $30,000)
30-Jun-15 109VRX Acquisition (Non Open Market) at $0 per share.
27-May-15 1,379REGN Sale at $513.39 - $513.39 per share.
(Proceeds of about $708,000)
22-May-15 1,607VRX Acquisition (Non Open Market) at $0 per share.
22-May-15 3,788REGN Disposition (Non Open Market) at $516.48 - $516.48 per share.
(Value of about $1,956,000)
22-May-15 6,667REGN Option Exercise at $293.53 - $293.53 per share.
(Cost of about $1,957,000)
15-May-15 1,826EW Acquisition (Non Open Market) at $0 per share.
22-Apr-15 811CREE Acquisition (Non Open Market) at $32.36 - $32.36 per share.
(Value of about $26,000)
31-Mar-15 122VRX Acquisition (Non Open Market) at $0 per share.
21-Jan-15 775CREE Acquisition (Non Open Market) at $33.87 - $33.87 per share.
(Value of about $26,000)


EDGAR Online: Get a Free Trial to EDGAR Online Premium | Full text Search


Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Data and information are provided by EDGAR Online, Inc. for informational purposes only and not intended for trading purposes. Yahoo!, EDGAR Online, Inc. shall have no liability for the accuracy of the information furnished or for delays, omissions or opinions expressed therein. You may not use the information for any illegal purpose or furnish the information to any person, firm, or branch office for commercial re-use or re-sale.

Questions or Comments?